Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Early body weight-supported overground walking training in patients with stroke in subacute phase compared to conventional physiotherapy: a randomized controlled pilot study.

Brunelli S, Iosa M, Fusco FR, Pirri C, Di Giunta C, Foti C, Traballesi M.

Int J Rehabil Res. 2019 Aug 12. doi: 10.1097/MRR.0000000000000363. [Epub ahead of print]

PMID:
31425349
2.

Modulation of Phospho-CREB by Systemically Administered Recombinant BDNF in the Hippocampus of the R6/2 Mouse Model of Huntington's Disease.

Paldino E, Giampà C, Montagna E, Angeloni C, Fusco FR.

Neurosci J. 2019 Feb 6;2019:8363274. doi: 10.1155/2019/8363274. eCollection 2019.

3.

Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease.

Giampà C, Alvino A, Magatti M, Silini AR, Cardinale A, Paldino E, Fusco FR, Parolini O.

J Cell Mol Med. 2019 Feb;23(2):1581-1592. doi: 10.1111/jcmm.14113. Epub 2018 Dec 25.

4.

Bilateral upper limb rehabilitation with videogame-based feedback in corticobasal degeneration: a case reports study.

Fusco FR, Iosa M, Fusco A, Paolucci S, Morone G.

Neurocase. 2018 Jun;24(3):156-160. doi: 10.1080/13554794.2018.1499938. Epub 2018 Jul 17.

PMID:
30015554
5.

Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Cardinale A, Fusco FR.

CNS Neurosci Ther. 2018 Apr;24(4):319-328. doi: 10.1111/cns.12834. Epub 2018 Mar 3. Review.

6.

Localization of neuroglobin in the brain of R6/2 mouse model of Huntington's disease.

Cardinale A, Fusco FR, Paldino E, Giampà C, Marino M, Nuzzo MT, D'Angelo V, Laurenti D, Straccia G, Fasano D, Sarnataro D, Squillaro T, Paladino S, Melone MAB.

Neurol Sci. 2018 Feb;39(2):275-285. doi: 10.1007/s10072-017-3168-2. Epub 2017 Nov 3.

PMID:
29101592
7.

Role of Phosphodiesterases in Huntington's Disease.

Fusco FR, Paldino E.

Adv Neurobiol. 2017;17:285-304. doi: 10.1007/978-3-319-58811-7_11. Review.

PMID:
28956337
8.

Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease.

Paldino E, Cardinale A, D'Angelo V, Sauve I, Giampà C, Fusco FR.

Front Neuroanat. 2017 Aug 2;11:61. doi: 10.3389/fnana.2017.00061. eCollection 2017.

9.

Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of DYT1 Dystonia.

D'Angelo V, Castelli V, Giorgi M, Cardarelli S, Saverioni I, Palumbo F, Bonsi P, Pisani A, Giampà C, Sorge R, Biagioni S, Fusco FR, Sancesario G.

J Neurosci. 2017 Feb 22;37(8):2112-2124. doi: 10.1523/JNEUROSCI.3207-15.2016. Epub 2017 Jan 23.

10.

Huntingtin polyQ Mutation Impairs the 17β-Estradiol/Neuroglobin Pathway Devoted to Neuron Survival.

Nuzzo MT, Fiocchetti M, Totta P, Melone MAB, Cardinale A, Fusco FR, Gustincich S, Persichetti F, Ascenzi P, Marino M.

Mol Neurobiol. 2017 Oct;54(8):6634-6646. doi: 10.1007/s12035-016-0337-x. Epub 2016 Dec 12.

PMID:
27957684
11.

Correction: Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington's Disease.

Giampà C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR.

PLoS One. 2016 Nov 23;11(11):e0166102. doi: 10.1371/journal.pone.0166102. eCollection 2016.

12.

Erratum: Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis.

Di Filippo M, de Iure A, Giampà C, Chiasserini D, Tozzi A, Orvietani PL, Ghiglieri V, Tantucci M, Durante V, Quiroga-Varela A, Mancini A, Costa C, Sarchielli P, Fusco FR, Calabresi P.

Sci Rep. 2016 Apr 13;6:23855. doi: 10.1038/srep23855. No abstract available.

13.

Persistent activation of microglia and NADPH oxidase [corrected] drive hippocampal dysfunction in experimental multiple sclerosis.

Di Filippo M, de Iure A, Giampà C, Chiasserini D, Tozzi A, Orvietani PL, Ghiglieri V, Tantucci M, Durante V, Quiroga-Varela A, Mancini A, Costa C, Sarchielli P, Fusco FR, Calabresi P.

Sci Rep. 2016 Feb 18;6:20926. doi: 10.1038/srep20926. Erratum in: Sci Rep. 2016;6:23855.

14.

Leap motion controlled videogame-based therapy for rehabilitation of elderly patients with subacute stroke: a feasibility pilot study.

Iosa M, Morone G, Fusco A, Castagnoli M, Fusco FR, Pratesi L, Paolucci S.

Top Stroke Rehabil. 2015 Aug;22(4):306-16. doi: 10.1179/1074935714Z.0000000036. Epub 2015 Feb 25.

PMID:
26258456
15.

PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.

Cardinale A, Paldino E, Giampà C, Bernardi G, Fusco FR.

PLoS One. 2015 Aug 7;10(8):e0134482. doi: 10.1371/journal.pone.0134482. eCollection 2015.

16.

Phosphodiesterases as therapeutic targets for Huntington's disease.

Fusco FR, Giampà C.

Curr Pharm Des. 2015;21(3):365-77. Review.

PMID:
25159076
17.

Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.

Giampà C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR.

PLoS One. 2013 May 20;8(5):e64037. doi: 10.1371/journal.pone.0064037. Print 2013. Erratum in: PLoS One. 2016 Nov 23;11(11):e0166102.

18.

Effects of central and peripheral inflammation on hippocampal synaptic plasticity.

Di Filippo M, Chiasserini D, Gardoni F, Viviani B, Tozzi A, Giampà C, Costa C, Tantucci M, Zianni E, Boraso M, Siliquini S, de Iure A, Ghiglieri V, Colcelli E, Baker D, Sarchielli P, Fusco FR, Di Luca M, Calabresi P.

Neurobiol Dis. 2013 Apr;52:229-36. doi: 10.1016/j.nbd.2012.12.009. Epub 2013 Jan 4.

PMID:
23295855
19.

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.

Leuti A, Laurenti D, Giampà C, Montagna E, Dato C, Anzilotti S, Melone MA, Bernardi G, Fusco FR.

Neurobiol Dis. 2013 Apr;52:104-16. doi: 10.1016/j.nbd.2012.11.016. Epub 2012 Dec 7.

PMID:
23220622
20.

Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission.

Arcangeli S, Tozzi A, Tantucci M, Spaccatini C, de Iure A, Costa C, Di Filippo M, Picconi B, Giampà C, Fusco FR, Amoroso S, Calabresi P.

J Cereb Blood Flow Metab. 2013 Feb;33(2):278-86. doi: 10.1038/jcbfm.2012.167. Epub 2012 Nov 14.

21.

Efficient cultivation of neural stem cells with controlled delivery of FGF-2.

Galderisi U, Peluso G, Di Bernardo G, Calarco A, D'Apolito M, Petillo O, Cipollaro M, Fusco FR, Melone MA.

Stem Cell Res. 2013 Jan;10(1):85-94. doi: 10.1016/j.scr.2012.09.001. Epub 2012 Sep 26.

22.

A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation.

Tozzi A, de Iure A, Marsili V, Romano R, Tantucci M, Di Filippo M, Costa C, Napolitano F, Mercuri NB, Borsini F, Giampà C, Fusco FR, Picconi B, Usiello A, Calabresi P.

PLoS One. 2012;7(6):e38312. doi: 10.1371/journal.pone.0038312. Epub 2012 Jun 8.

23.

Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition.

Fusco FR, Anzilotti S, Giampà C, Dato C, Laurenti D, Leuti A, Colucci D'Amato L, Perrone L, Bernardi G, Melone MA.

Neurobiol Dis. 2012 Apr;46(1):225-33. doi: 10.1016/j.nbd.2012.01.011. Epub 2012 Jan 28.

PMID:
22311347
24.

Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease.

Bagetta V, Picconi B, Marinucci S, Sgobio C, Pendolino V, Ghiglieri V, Fusco FR, Giampà C, Calabresi P.

J Neurosci. 2011 Aug 31;31(35):12513-22. doi: 10.1523/JNEUROSCI.2236-11.2011.

25.

The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease.

Tozzi A, de Iure A, Di Filippo M, Tantucci M, Costa C, Borsini F, Ghiglieri V, Giampà C, Fusco FR, Picconi B, Calabresi P.

J Neurosci. 2011 Feb 2;31(5):1850-62. doi: 10.1523/JNEUROSCI.4082-10.2011.

26.

Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease.

Anzilotti S, Giampà C, Laurenti D, Perrone L, Bernardi G, Melone MA, Fusco FR.

Brain Res Bull. 2012 Feb 10;87(2-3):350-8. doi: 10.1016/j.brainresbull.2011.01.009. Epub 2011 Jan 25.

PMID:
21272617
27.

Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.

Picconi B, Bagetta V, Ghiglieri V, Paillè V, Di Filippo M, Pendolino V, Tozzi A, Giampà C, Fusco FR, Sgobio C, Calabresi P.

Brain. 2011 Feb;134(Pt 2):375-87. doi: 10.1093/brain/awq342. Epub 2010 Dec 22.

PMID:
21183486
28.

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR.

PLoS One. 2010 Oct 15;5(10):e13417. doi: 10.1371/journal.pone.0013417.

29.

Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition.

Paillé V, Picconi B, Bagetta V, Ghiglieri V, Sgobio C, Di Filippo M, Viscomi MT, Giampà C, Fusco FR, Gardoni F, Bernardi G, Greengard P, Di Luca M, Calabresi P.

J Neurosci. 2010 Oct 20;30(42):14182-93. doi: 10.1523/JNEUROSCI.2149-10.2010.

30.

A case of PANDAS treated with tetrabenazine and tonsillectomy.

Fusco FR, Pompa A, Bernardi G, Ottaviani F, Giampà C, Laurenti D, Morello M, Bernardini S, Nuccetelli M, Sabatini U, Paolucci S.

J Child Neurol. 2010 May;25(5):614-5. doi: 10.1177/0883073809355824. Epub 2010 Mar 5.

PMID:
20207613
31.

TrkB/BDNF-dependent striatal plasticity and behavior in a genetic model of epilepsy: modulation by valproic acid.

Ghiglieri V, Sgobio C, Patassini S, Bagetta V, Fejtova A, Giampà C, Marinucci S, Heyden A, Gundelfinger ED, Fusco FR, Calabresi P, Picconi B.

Neuropsychopharmacology. 2010 Jun;35(7):1531-40. doi: 10.1038/npp.2010.23. Epub 2010 Mar 3.

32.

The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles.

Massa R, Panico MB, Caldarola S, Fusco FR, Sabatelli P, Terracciano C, Botta A, Novelli G, Bernardi G, Loreni F.

Neuropathol Appl Neurobiol. 2010 Jun;36(4):275-84. doi: 10.1111/j.1365-2990.2010.01068.x. Epub 2009 Nov 20.

PMID:
20102514
33.

Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.

Giampà C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco FR.

Eur J Neurosci. 2009 Mar;29(5):902-10. doi: 10.1111/j.1460-9568.2009.06649.x.

PMID:
19291221
34.

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.

Giampà C, Patassini S, Borreca A, Laurenti D, Marullo F, Bernardi G, Menniti FS, Fusco FR.

Neurobiol Dis. 2009 Jun;34(3):450-6. doi: 10.1016/j.nbd.2009.02.014. Epub 2009 Mar 9.

PMID:
19281846
35.

Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease.

Patassini S, Giampà C, Martorana A, Bernardi G, Fusco FR.

Neurosci Lett. 2008 Dec 19;448(1):166-9. doi: 10.1016/j.neulet.2008.10.023. Epub 2008 Oct 14.

PMID:
18938217
36.

Quantification of the probability of reaching mobility independence at discharge from a rehabilitation hospital in nonwalking early ischemic stroke patients: a multivariate study.

Paolucci S, Bragoni M, Coiro P, De Angelis D, Fusco FR, Morelli D, Venturiero V, Pratesi L.

Cerebrovasc Dis. 2008;26(1):16-22. doi: 10.1159/000135648. Epub 2008 May 30.

PMID:
18511867
37.

Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease.

DeMarch Z, Giampà C, Patassini S, Bernardi G, Fusco FR.

Neurobiol Dis. 2008 Jun;30(3):375-87. doi: 10.1016/j.nbd.2008.02.010. Epub 2008 Mar 7.

PMID:
18424161
38.

Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions.

De March Z, Zuccato C, Giampà C, Patassini S, Bari M, Gasperi V, De Ceballos ML, Bernardi G, Maccarrone M, Cattaneo E, Fusco FR.

Neuroscience. 2008 Mar 27;152(3):734-40. doi: 10.1016/j.neuroscience.2007.11.044. Epub 2007 Dec 8.

PMID:
18313855
39.

Neuroprotective effect of hydrogen peroxide on an in vitro model of brain ischaemia.

Nisticò R, Piccirilli S, Cucchiaroni ML, Armogida M, Guatteo E, Giampà C, Fusco FR, Bernardi G, Nisticò G, Mercuri NB.

Br J Pharmacol. 2008 Mar;153(5):1022-9. doi: 10.1038/sj.bjp.0707587. Epub 2008 Jan 28.

40.

Immunohistochemical localization of TRPC6 in the rat substantia nigra.

Giampà C, DeMarch Z, Patassini S, Bernardi G, Fusco FR.

Neurosci Lett. 2007 Sep 13;424(3):170-4. Epub 2007 Aug 9.

PMID:
17723267
41.

Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.

DeMarch Z, Giampà C, Patassini S, Martorana A, Bernardi G, Fusco FR.

Neurobiol Dis. 2007 Feb;25(2):266-73. Epub 2006 Dec 20.

PMID:
17184995
42.

Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.

Scattoni ML, Valanzano A, Pezzola A, March ZD, Fusco FR, Popoli P, Calamandrei G.

Behav Brain Res. 2007 Jan 25;176(2):216-21. Epub 2006 Nov 22.

PMID:
17123640
43.

Is sex a prognostic factor in stroke rehabilitation? A matched comparison.

Paolucci S, Bragoni M, Coiro P, De Angelis D, Fusco FR, Morelli D, Venturiero V, Pratesi L.

Stroke. 2006 Dec;37(12):2989-94. Epub 2006 Nov 2.

PMID:
17082475
44.

Distribution of TRPC1 receptors in dendrites of rat substantia nigra: a confocal and electron microscopy study.

Martorana A, Giampà C, DeMarch Z, Viscomi MT, Patassini S, Sancesario G, Bernardi G, Fusco FR.

Eur J Neurosci. 2006 Aug;24(3):732-8.

PMID:
16930403
45.

Neurotensin effects on N-type calcium currents among rat pallidal neurons: an electrophysiological and immunohistochemical study.

Martorana A, Martella G, D'Angelo V, Fusco FR, Spadoni F, Bernardi G, Stefani A.

Synapse. 2006 Oct;60(5):371-83.

PMID:
16838364
46.

Cellular localization of TRPC5 in the substantia nigra of rat.

De March Z, Giampà C, Patassini S, Bernardi G, Fusco FR.

Neurosci Lett. 2006 Jul 10;402(1-2):35-9. Epub 2006 Apr 25.

PMID:
16635549
47.

Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.

Giampà C, DeMarch Z, D'Angelo V, Morello M, Martorana A, Sancesario G, Bernardi G, Fusco FR.

Eur J Neurosci. 2006 Jan;23(1):11-20.

PMID:
16420411
48.

Rehabilitation of left brain-damaged ischemic stroke patients: the role of comprehension language deficits. A matched comparison.

Paolucci S, Matano A, Bragoni M, Coiro P, De Angelis D, Fusco FR, Morelli D, Pratesi L, Venturiero V, Bureca I.

Cerebrovasc Dis. 2005;20(5):400-6. Epub 2005 Oct 3.

PMID:
16205059
49.

Cellular localization of TRPC3 channel in rat brain: preferential distribution to oligodendrocytes.

Fusco FR, Martorana A, Giampà C, De March Z, Vacca F, Tozzi A, Longone P, Piccirilli S, Paolucci S, Sancesario G, Mercuri NB, Bernardi G.

Neurosci Lett. 2004 Jul 22;365(2):137-42.

PMID:
15245795
50.

Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study.

Fusco FR, Martorana A, Giampà C, De March Z, Farini D, D'Angelo V, Sancesario G, Bernardi G.

Synapse. 2004 Sep 1;53(3):159-67.

PMID:
15236348

Supplemental Content

Loading ...
Support Center